SCHEMBL5848628

SCHEMBL5848628

Cc1nn2c(-c3ccc(Cl)cc3Cl)cccc2c1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 1/20 0.49
NPC1 O15118 1/20 0.47
HSD11B1 P28845 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
DPP4 P27487 7/20 0.40
LMNA P02545 2/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
DPP8 Q6V1X1 3/20 0.39
DPP9 Q86TI2 3/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
CRHR1 P34998 4/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1942440 0.83 CRHR1 (0.51) EGLN2NPC1DPP4LMNACRHR1
SCHEMBL5847778 0.79 CRHR1 (0.49) EGLN2NPC1DPP4CRHR1
SCHEMBL5849016 0.79 HSD11B1 (0.45) EGLN2NPC1HSD11B1L3MBTL1LMNA
SCHEMBL5849283 0.78 DPP4 (0.45) NPC1HSD11B1DPP4LMNAHSP90AA1
SCHEMBL5847263 0.77 CRHR1 (0.60) CRHR1
SCHEMBL5847147 0.77 CRHR1 (0.53) EGLN2CRHR1
SCHEMBL5847373 0.74 CRHR1 (0.55) EGLN2NPC1L3MBTL1CRHR1
SCHEMBL5848807 0.73 NPC1 (0.60) EGLN2NPC1HSD11B1DPP4LMNA
SCHEMBL5847745 0.71 NPC1 (0.36) EGLN2NPC1DPP4DPP8CRHR1
SCHEMBL1944929 0.70 CRHR1 (0.46) EGLN2NPC1DPP4LMNADPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151109-B2 Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators PHARMACIA & UPJOHN COMPANY LLC (US) 2006-12-19 US disclosed
EP-1485384-A1 PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS Pharmacia & Upjohn Company LLC (US) 2004-12-15 EP disclosed
US-20040002511-A1 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators PHARMACIA & UPJOHN COMPANY 2004-01-01 US disclosed
WO-2003078435-A1 PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS PHARMACIA & UPJOHN COMPANY LLC (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002511-A1 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators CRHR1, HTR5A, CRH EGLN2 1778/4885NPC1 1923/4885HSD11B1 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.